Sapient Capital LLC Cuts Stock Position in UnitedHealth Group Incorporated $UNH

Sapient Capital LLC decreased its stake in UnitedHealth Group Incorporated (NYSE:UNH) by 44.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,704 shares of the healthcare conglomerate’s stock after selling 1,387 shares during the quarter. Sapient Capital LLC’s holdings in UnitedHealth Group were worth $708,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Syon Capital LLC boosted its holdings in UnitedHealth Group by 25.0% in the 2nd quarter. Syon Capital LLC now owns 11,562 shares of the healthcare conglomerate’s stock worth $4,806,000 after buying an additional 2,316 shares during the last quarter. denkapparat Operations GmbH purchased a new position in shares of UnitedHealth Group in the second quarter valued at approximately $382,000. TD Waterhouse Canada Inc. increased its position in shares of UnitedHealth Group by 10.1% during the second quarter. TD Waterhouse Canada Inc. now owns 150,953 shares of the healthcare conglomerate’s stock worth $64,425,000 after purchasing an additional 13,864 shares in the last quarter. Premier Path Wealth Partners LLC lifted its holdings in UnitedHealth Group by 32.1% in the 2nd quarter. Premier Path Wealth Partners LLC now owns 7,830 shares of the healthcare conglomerate’s stock valued at $3,254,000 after purchasing an additional 1,902 shares in the last quarter. Finally, Lakeshore Financial Planning Inc. acquired a new stake in UnitedHealth Group during the 2nd quarter worth $221,000. 87.86% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at UnitedHealth Group

In other UnitedHealth Group news, CEO Patrick Conway sold 1,169 shares of UnitedHealth Group stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $390.00, for a total transaction of $455,910.00. Following the completion of the sale, the chief executive officer directly owned 15,328 shares in the company, valued at $5,977,920. This trade represents a 7.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.19% of the stock is currently owned by corporate insiders.

More UnitedHealth Group News

Here are the key news stories impacting UnitedHealth Group this week:

• Positive Sentiment: Earnings and guidance have improved. UnitedHealth recently exceeded quarterly earnings and revenue expectations, raised its 2026 adjusted EPS outlook to $19.50–$20.00, and benefited from better medical-cost trends. Optum’s momentum and a greater focus on profitable businesses are also supporting the turnaround. UnitedHealth’s Earnings Beat And Cost Controls Could Be A Game Changer
• Positive Sentiment: Reducing prior authorizations could improve member and provider relationships. UnitedHealthcare plans to eliminate authorization requirements for roughly 1,700 services, including certain cardiology, laboratory, therapy, orthopedic and home-health procedures, beginning October 1. Less administrative friction could improve customer satisfaction, access to care and long-term retention. UnitedHealth Group To Cut Prior Authorizations For 1,700 Services
• Neutral Sentiment: Healthcare’s defensive characteristics may attract investors. Sector rotation driven by interest rates, oil prices and employment conditions could favor defensive healthcare stocks over higher-growth areas. However, analyst commentary remains mixed on whether UNH is still attractively valued after its roughly 39% six-month recovery.
• Negative Sentiment: Investors are questioning medical-cost discipline. Removing approval barriers may accelerate care and payments, but it could also weaken a key mechanism used to manage utilization and expenses. The market is watching whether faster approvals undermine margins. UnitedHealth Falls as 30% of Approval Barriers Vanish
• Negative Sentiment: Valuation leaves less room for disappointment. After a substantial rebound, UNH trades near $400 per share, leading some analysts to argue that investors have already priced in much of the recovery while margins and certain business challenges still need to improve.

Analysts Set New Price Targets

UNH has been the topic of several research reports. Bank of America reissued a “buy” rating on shares of UnitedHealth Group in a research note on Monday, July 20th. Royal Bank Of Canada increased their price objective on shares of UnitedHealth Group from $463.00 to $478.00 and gave the company an “outperform” rating in a report on Friday, July 17th. Barclays boosted their target price on UnitedHealth Group from $429.00 to $441.00 and gave the stock an “overweight” rating in a report on Monday, July 20th. Leerink Partners lifted their price objective on UnitedHealth Group from $400.00 to $462.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 17th. Finally, Erste Group Bank cut UnitedHealth Group from a “buy” rating to a “hold” rating in a report on Thursday, August 27th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, UnitedHealth Group presently has a consensus rating of “Moderate Buy” and an average price target of $456.56.

UnitedHealth Group Stock Down 1.0%

Shares of NYSE UNH opened at $396.79 on Friday. The company has a market capitalization of $356.15 billion, a P/E ratio of 25.53, a P/E/G ratio of 1.51 and a beta of 0.61. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.78 and a quick ratio of 0.78. The company has a 50 day simple moving average of $411.65 and a 200-day simple moving average of $364.16. UnitedHealth Group Incorporated has a 1 year low of $255.96 and a 1 year high of $461.62.

UnitedHealth Group (NYSE:UNH) last released its quarterly earnings data on Thursday, July 16th. The healthcare conglomerate reported $6.38 EPS for the quarter, beating analysts’ consensus estimates of $4.94 by $1.44. UnitedHealth Group had a return on equity of 16.53% and a net margin of 3.14%.The firm had revenue of $112.03 billion for the quarter, compared to analysts’ expectations of $110.81 billion. During the same period in the prior year, the firm posted $4.08 earnings per share. The firm’s quarterly revenue was up .4% on a year-over-year basis. UnitedHealth Group has set its FY 2026 guidance at 19.500-20.000 EPS. On average, equities research analysts predict that UnitedHealth Group Incorporated will post 19.82 earnings per share for the current year.

UnitedHealth Group Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 22nd. Shareholders of record on Monday, September 14th will be given a $2.32 dividend. The ex-dividend date of this dividend is Monday, September 14th. This represents a $9.28 dividend on an annualized basis and a yield of 2.3%. UnitedHealth Group’s dividend payout ratio is presently 59.72%.

About UnitedHealth Group

UnitedHealth Group Inc is a diversified health care company headquartered in Minnetonka, Minnesota, that operates two primary business platforms: UnitedHealthcare and Optum. Founded in 1977, the company provides a broad range of health benefits and health care services to individuals, employers, governmental entities and other organizations. Its operations span commercial employer-sponsored plans, individual and Medicare and Medicaid programs, and services for customers and health systems in the United States and selected international markets.

UnitedHealthcare is the company’s benefits business, administering health plans and networks, managing provider relationships, and offering coverage products for employers, individuals, and government-sponsored programs.